Real-World Comparative Analysis of Polatuzumab Vedotin-Based Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone versus Standard Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Diffuse L
Pola-R-CHP achieved higher interim and end-of-treatment response rates than R-CHOP with a comparable safety profile. However, survival outcomes remain immature, and given the small matched sample size (n = 72), these findings should be interpreted cautiously and confirmed in larger prospective studies.
Authors
- Daobin Zhou (ORCID: https://orcid.org/0000-0002-1592-1932)
- Ziqian Wang (ORCID: https://orcid.org/0000-0003-4537-8739)
- Wei Zhang (ORCID: https://orcid.org/0000-0001-6241-4207)
- Chong Wei (ORCID: https://orcid.org/0000-0001-9690-8555)
- Kaini Shen (ORCID: https://orcid.org/0000-0003-2381-339X)
- Huacong Cai
- Danqing Zhao
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
Publication Details
- Journal
- Oncology
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1159/000549477
- Citations
- 1
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.47